Category: Uncategorized

Last March 18, the European Medicines Agency (EMA) announced the selected consortium to monitor possible adverse events to COVID-19 vaccines in Europe for the next 3 years.

 

The consortium, led by the Netherlands, includes 13 countries and the Portuguese participation is coordinated by UFC, leaded by Prof. Francisco Batel Marques. Entitled “Monitoring the safety of covid-19 vaccines in the EU”, the study has the contribution of Portugal, through a collaboration agreement between the pharmacovigilance units of Coimbra (AIBILI-UFC and Faculty of Pharmacy of UC), Porto (Faculty of Medicine) and Lisbon (Faculty of Pharmacy).

 

“It is very important, from the point of view of public health, to have reliable information on the safety of vaccines”, said Prof. Francisco Batel Marques, observing also that the time of research and development was relatively short.

 

The project is now in preparation to start in agreement with all details approved by EMA.

 

 

More information: https://expresso.pt/coronavirus/2021-03-22-Covid-19.-Portugal-integra-projeto-europeu-para-fiscalizar-seguranca-das-vacinas-1c594763

We have receive our renewal of Data Centre (DC) certification by ECRIN – European Clinical Research Infrastructure Network!

This is an important mark for AIBILI as it stands that our DC meets the ECRIN requirements for IT and Data Management within Clinical Trials, as per the conclusions of an independent risk based audit.

Moreover, we were the first European DC to obtain a certification renewal!

 

Nesta edição do boletim “FARMACOVIGILÂNCIA: Atualizações de segurança de medicamentos” informa-se acerca dos casos de hipertensão grave e síndrome de encefalopatia posterior reversível associada à utilização de niparaib, do risco de hipofosfatemia sintomática associada à carboximaltose férrica, do risco aumentado de malformações congénitas quando o modafinil é utilizada na gravidez e sobre precauções a ter no tratamento com eritromicina. Destaca-se ainda a informação de segurança sobre vacinas aprovadas para a COVID-19 e informa-se dos tratamentos aprovados para a COVID-19. Por último, é apresentada a atividade científica da Unidade de Farmacovigilância de Coimbra (UFC) e os resultados da sua atividade no quarto trimestre de 2020.

Consulte: Farmacovigilancia-Atualizacoes-de-seguranca-de-medicamentos-Vol7-N4

AIBILI and Pathway Health Consulting are organizing a session focused on Funding and Prices of medicines in Portugal

 

The session will opened by Prof. Francisco Batel-Marques and count with a presentation by Cláudia Furtado (Head of the Health Technology Assessment, Pricing and Reimbursement, INFARMED, I.P.) followed by Q&A.

 

Registration here: http://z08er.qr.ai

AIBILI researchers Luis Mendes and Sofia Gonçalves will be presenting on the EATRIS AI SYMPOSIUM – “How the emerging role of artificial intelligence (AI) in translational medicine can jump-start a new era in medical care”, on January 13 and 19!

 

Their presentations will focus on:

 

– Mobile deep learning architectures for AMD and DR screening (Sofia Gonçalves, January 13, 14:45 (CET))

 

– Automatic detection of pathological OCT volumes based on structural and OCTA metrics (Luis Mendes, January 19, 15:00 (CET))

 

Program and registration (free but mandatory) here: https://eatris.eu/events/eatris-ai-symposium-how-the-emerging-role-of-artificial-intelligence-ai-in-translational-medicine-can-jump-start-a-new-era-in-medical-care/

The JoinHealth – Autumn welcome webinar dedicated to Clinical research data will count with the participation of Rita Fernandes and Carlos Domingues from AIBILI – Association for Innovation and Biomedical Research on Light and Image. The webinar will take place on November 17, at 14:30.

Registration here https://lnkd.in/dSGjUxP (free, but mandatory)

Nesta edição do boletim “FARMACOVIGILÂNCIA: Atualizações de segurança de medicamentos” informa-se acerca do risco de aneurisma e dissecção da artéria em doentes sob terapêutica com inibidores do VEGF, quando administrado por via sistémica; os riscos e questões relacionadas com a segurança de Isotretinoína (Roaccutane▼), Baricitinib (Olumiant▼) e insulinas (todos os tipos). Destaca-se ainda o apoio da Agência Europeia do Medicamento (EMA) no uso da dexametasona em doentes COVID-19 e os potenciais tratamentos e vacinas que se encontram sob investigação para COVID-19. Por último, são apresentados os resultados da atividade da Unidade de Farmacovigilância de Coimbra (UFC) no terceiro trimestre de 2020.

Consulte: Farmacovigilância – Atualizações de segurança de medicamentos, Vol.7 – N.3

Prof. Cunha-Vaz talks about ophthalmology, AIBILI and Coimbra.

Please read complete interview here.

AIBILI is proud to announce that our researcher Prof. Rufino Silva was awarded with the 2020 European Society of Retina Specialists (EURETINA) Clinical Research Award with the project “Metabolomics: A Tool for Investigating the Progression of Age-related Macular Degeneration”.

This project is co-leaded by Doctor Inês Laíns and results from a collaboration with the Massachusetts Eye and Ear (MEE), from the HMX – Harvard Medical School

Congratulations to the team for this prize, which will allow the study of innovative tools to study mechanisms of progression of Age-related Macular Degeneration, and to identify new potential biomarkers and therapeutic strategies!